Tromboprophylaxis

(At the request of the Superior Health Council and the Federal Agency for Medicines and Health products– April-May 2020)

COVID-19 increases the risk of thromboembolic problems, both in the venous and arterial circulations, which increases the risk of death significantly.

On April 7, Sciensano recommended replacing treatment with oral anticoagulants in hospitalised patients (before admission) with curative low molecular weight heparin. The reason for this was the possible drug interactions and difficulties in adjusting the dose of oral anticoagulants. In addition, the Belgian Society on Thrombosis and haemostasis (BSTH) had published algorithms for COVID-19 positive patients in hospital (in intensive care or otherwise) and for ambulatory patients. 

As the scientific evidence evolves constantly, we performed a rapid literature review to complement the literature review already conducted. The conclusion was that the algorithms from the BSTH were in line with international recommendations but that guidance was lacking for pregnant women or women in the post-partum phase. As a result, the BSTH started an urgent consensus process to update the algorithms supplementing them with background information and recommendations for pregnant and post-partum women. 

Download the document : Tromboprophylaxis  

Document
Contact
Karin Rondia (FR)
+32 (0)2 287 33 48
+32 (0)475 769 766
ANNUAL REPORT
Published on: 
2021/09/22